AU2019209436B2 - Methods for colon cancer detection and treatment monitoring - Google Patents

Methods for colon cancer detection and treatment monitoring Download PDF

Info

Publication number
AU2019209436B2
AU2019209436B2 AU2019209436A AU2019209436A AU2019209436B2 AU 2019209436 B2 AU2019209436 B2 AU 2019209436B2 AU 2019209436 A AU2019209436 A AU 2019209436A AU 2019209436 A AU2019209436 A AU 2019209436A AU 2019209436 B2 AU2019209436 B2 AU 2019209436B2
Authority
AU
Australia
Prior art keywords
score
expression level
therapy
subject
colon cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019209436A
Other languages
English (en)
Other versions
AU2019209436A1 (en
Inventor
Ignat Drozdov
Mark Kidd
Irvin Mark MODLIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liquid Biopsy Research LLC
Original Assignee
Liquid Biopsy Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liquid Biopsy Research LLC filed Critical Liquid Biopsy Research LLC
Publication of AU2019209436A1 publication Critical patent/AU2019209436A1/en
Application granted granted Critical
Publication of AU2019209436B2 publication Critical patent/AU2019209436B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioethics (AREA)
  • Databases & Information Systems (AREA)
  • Evolutionary Computation (AREA)
AU2019209436A 2018-01-22 2019-01-22 Methods for colon cancer detection and treatment monitoring Active AU2019209436B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862620015P 2018-01-22 2018-01-22
US62/620,015 2018-01-22
PCT/US2019/014490 WO2019144099A1 (en) 2018-01-22 2019-01-22 Methods for colon cancer detection and treatment monitoring

Publications (2)

Publication Number Publication Date
AU2019209436A1 AU2019209436A1 (en) 2020-08-06
AU2019209436B2 true AU2019209436B2 (en) 2025-06-05

Family

ID=65279827

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019209436A Active AU2019209436B2 (en) 2018-01-22 2019-01-22 Methods for colon cancer detection and treatment monitoring

Country Status (15)

Country Link
US (3) US11414707B2 (https=)
EP (1) EP3743534B1 (https=)
JP (1) JP7297770B2 (https=)
KR (1) KR20200113237A (https=)
CN (1) CN112004945B (https=)
AU (1) AU2019209436B2 (https=)
BR (1) BR112020014737A2 (https=)
CA (1) CA3088754A1 (https=)
DK (1) DK3743534T3 (https=)
ES (1) ES2917629T3 (https=)
IL (1) IL276089B2 (https=)
MX (1) MX2020007771A (https=)
PL (1) PL3743534T3 (https=)
SG (1) SG11202006974WA (https=)
WO (1) WO2019144099A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3743534T3 (pl) 2018-01-22 2022-09-05 Liquid Biopsy Research LLC Sposoby wykrywania nowotworu okrężnicy i monitorowania leczenia
MX2022004372A (es) 2019-10-10 2022-07-27 Liquid Biopsy Res Llc Composiciones, métodos y kits para la estabilización de muestras biológicas y de arn.
US11809379B2 (en) * 2019-11-19 2023-11-07 International Business Machines Corporation Storage tiering for deduplicated storage environments
CN111157745A (zh) * 2020-01-17 2020-05-15 上海交通大学 人snrpa蛋白在肺癌复发或转移监测中的用途
CN115475247B (zh) * 2021-06-16 2024-02-20 厦门大学 β2-微球蛋白或其抑制剂的制药用途
KR102823777B1 (ko) * 2021-10-15 2025-06-23 한국과학기술원 인공지능을 이용하여 유전체 염기서열로 질환 진단 및 예측 방법, 그 시스템
CN113921079B (zh) * 2021-12-06 2022-03-18 四川省肿瘤医院 基于免疫相关基因的msi预测模型构建方法
CN121137146B (zh) * 2025-07-28 2026-04-07 首钢医院有限公司 检测基因组合物的试剂在制备预测结直肠癌患者远端切缘长度的产品中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2169078A1 (en) * 2008-09-26 2010-03-31 Fundacion Gaiker Methods and kits for the diagnosis and the staging of colorectal cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2169077A1 (en) * 2008-09-19 2010-03-31 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Methods and compositions for diagnosing an adenocarcinoma
KR101051435B1 (ko) * 2008-10-22 2011-07-22 한국생명공학연구원 대장암 관련 마커를 이용한 대장암 진단 키트 및 이를 이용한 대장암 진단 방법
KR101073875B1 (ko) 2008-11-28 2011-10-14 한국생명공학연구원 대장암 진단 마커 및 이를 이용한 대장암 진단방법
SG10201401722XA (en) 2009-05-01 2014-08-28 Genomic Health Inc Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer andresponse to chemotherapy
EP2309002A1 (en) * 2009-09-29 2011-04-13 Centre National de la Recherche Scientifique (CNRS) Signature for the diagnosis of colorectal cancer aggressiveness
ES2525382T3 (es) * 2010-03-31 2014-12-23 Sividon Diagnostics Gmbh Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino
EP2426216A1 (en) * 2010-09-01 2012-03-07 Institut Gustave Roussy (IGR) Prognostic and/or predictive biomarkers and biological applications thereof
CN103403187A (zh) 2011-01-18 2013-11-20 艾沃锐斯特基因有限公司 结肠直肠癌复发的预后特征
JP2014509189A (ja) 2011-01-25 2014-04-17 アルマック ダイアグノスティックス リミテッド 結腸ガン遺伝子発現シグネチャーおよび使用方法
US20150226744A1 (en) * 2012-09-17 2015-08-13 Ait Austrian Institute Of Technology Gmbh Colon Cancer Diagnostic Method and Means
WO2014085826A2 (en) * 2012-11-30 2014-06-05 Applied Proteomics, Inc. Method for evaluation of presence of or risk of colon tumors
EP2985296A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
PL3743534T3 (pl) 2018-01-22 2022-09-05 Liquid Biopsy Research LLC Sposoby wykrywania nowotworu okrężnicy i monitorowania leczenia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2169078A1 (en) * 2008-09-26 2010-03-31 Fundacion Gaiker Methods and kits for the diagnosis and the staging of colorectal cancer

Also Published As

Publication number Publication date
CA3088754A1 (en) 2019-07-25
JP2021511057A (ja) 2021-05-06
EP3743534A1 (en) 2020-12-02
SG11202006974WA (en) 2020-08-28
IL276089A (en) 2020-08-31
IL276089B2 (en) 2024-07-01
AU2019209436A1 (en) 2020-08-06
DK3743534T3 (da) 2022-06-20
CN112004945A (zh) 2020-11-27
EP3743534B1 (en) 2022-03-23
KR20200113237A (ko) 2020-10-06
US20230220482A1 (en) 2023-07-13
PL3743534T3 (pl) 2022-09-05
WO2019144099A1 (en) 2019-07-25
MX2020007771A (es) 2020-09-03
IL276089B1 (en) 2024-03-01
US20250243553A1 (en) 2025-07-31
BR112020014737A2 (pt) 2020-12-08
JP7297770B2 (ja) 2023-06-26
US20190226030A1 (en) 2019-07-25
US11414707B2 (en) 2022-08-16
ES2917629T3 (es) 2022-07-11
CN112004945B (zh) 2025-02-14
US12305240B2 (en) 2025-05-20

Similar Documents

Publication Publication Date Title
AU2019209436B2 (en) Methods for colon cancer detection and treatment monitoring
AU2019201577B2 (en) Cancer diagnostics using biomarkers
US20190300967A1 (en) Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature
AU2018210695B2 (en) Molecular subtyping, prognosis, and treatment of bladder cancer
AU2012352153B2 (en) Cancer diagnostics using non-coding transcripts
KR102921718B1 (ko) 전립선암 검출 및 치료 방법
US20090118175A1 (en) Compositions and Methods for Detection, Prognosis and Treatment of Breast Cancer
KR20220094218A (ko) 핵산 분자의 분석 방법 및 시스템
AU2024227427A1 (en) Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
EP4103752A2 (en) Methods and compositions for identifying castration resistant neuroendocrine prostate cancer
AU2025210861A1 (en) Predicting peptide receptor radiotherapy using a gene expression assay
KR20240005018A (ko) 핵산 분자를 분석하기 위한 방법 및 시스템
US20040166105A1 (en) Compositions and methods relating to breast specific genes and proteins
KR20070099564A (ko) 급성 골수성 백혈병 환자를 평가하는 방법
US12478665B2 (en) Cancer vaccine compositions and methods for using same to prevent and/or treat cancer
US20030092898A1 (en) Compositions and methods relating to breast specific genes and proteins
US20030175715A1 (en) Compositions and methods relating to breast specific genes and proteins
US20030175707A1 (en) Compositions and methods relating to prostate specific genes and proteins
US20020192666A1 (en) Compositions and methods relating to colon specific genes and proteins
HK40060652A (en) Methods and systems for analyzing nucleic acid molecules
US20030039986A1 (en) Compositions and methods relating to prostate specific genes and proteins
KR20220122197A (ko) 비근침윤성 방광암의 예후 예측을 위한 바이오마커 및 이의 용도
WO2005044075A2 (en) Compositions, splice variants and methods relating to breast specific genes and proteins

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)